Stephen L. Hoffman | Academic Influence

Stephen L. Hoffman's AcademicInfluence.com Rankings

Stephen L. Hoffman

Computer Science

#4631

World Rank

#4884

Historical Rank

Machine Learning

#1027

World Rank

#1042

Historical Rank

Artificial Intelligence

#1250

World Rank

#1273

Historical Rank

Database

#1933

World Rank

#2028

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Stephen L. Hoffman's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Stephen L. Hoffman Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Stephen L. Hoffman is an American physician-scientist, tropical medicine specialist and vaccinologist, who is the founder and chief executive and scientific officer of Sanaria Inc., a company dedicated to developing PfSPZ vaccines to prevent malaria.

(See a Problem?)

Stephen L. Hoffman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Genome sequence of the human malaria parasite Plasmodium falciparum (2002) (4255)
The Genome Sequence of the Malaria Mosquito Anopheles gambiae (2002) (2020)
Comparative genomics of the neglected human malaria parasite Plasmodium vivax (2008) (787)
Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. (2002) (732)
Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii (2002) (729)
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine (2013) (693)
Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment? (2006) (600)
Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum. (1998) (482)
Funding for malaria genome sequencing (1997) (465)
Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. (1994) (459)
Primaquine therapy for malaria. (2004) (422)
SAFETY AND EFFICACY OF A RECOMBINANT DNA PLASMODIUM FALCIPARUM SPOROZOITE VACCINE (1987) (406)
The Complexity of Protective Immunity Against Liver-Stage Malaria1 2 (2000) (344)
Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay (1994) (328)
Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria (2010) (310)
Sterile protection against human malaria by chemoattenuated PfSPZ vaccine (2017) (296)
Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue (2011) (288)
Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. (1984) (282)
Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity (1996) (280)
Protection against malaria at 1 year and immune correlates following PfSPZ vaccination (2016) (277)
Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. (1998) (260)
A Research Agenda for Malaria Eradication: Vaccines (2011) (248)
Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine (2003) (245)
Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. (1998) (244)
Induction of CD4+ T cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine (2001) (242)
Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data (2003) (238)
Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine (1991) (235)
Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. (1991) (226)
Characterization of Plasmodium falciparum sporozoite surface protein 2. (1992) (218)
Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. (1987) (218)
Comparative analysis of apicomplexa and genomic diversity in eukaryotes. (2004) (214)
Vivax malaria resistant to treatment and prophylaxis with chloroquine (1993) (213)
Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes (1990) (208)
IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. (1999) (204)
Interleukin 12 induction of interferon gamma-dependent protection against malaria. (1994) (201)
Cellular mechanisms of nonspecific immunity to intracellular infection: cytokine-induced synthesis of toxic nitrogen oxides from L-arginine by macrophages and hepatocytes. (1990) (199)
Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. (1997) (198)
Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. (2017) (196)
Malaria vaccine development: a multi-immune response approach (1996) (190)
Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection (2017) (188)
A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. (2013) (187)
Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. (1991) (185)
A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. (1998) (184)
Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. (1997) (178)
Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. (2017) (175)
IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. (1991) (175)
Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. (1989) (173)
Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. (1999) (172)
Interleukin-12- and Gamma Interferon-Dependent Protection against Malaria Conferred by CpG Oligodeoxynucleotide in Mice (2001) (168)
Malaria Epitopes Expressed on the surface of Recombinant Tobacco Mosaic Virus (1995) (164)
Do DNA vaccines induce autoimmune disease? (1997) (164)
Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. (1987) (162)
Malaria transmission dynamics at a site in northern Ghana proposed for testing malaria vaccines (2004) (158)
Controlled Human Malaria Infections by Intradermal Injection of Cryopreserved Plasmodium falciparum Sporozoites (2013) (153)
Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates (1992) (152)
Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. (1991) (151)
A public antibody lineage that potently inhibits malaria infection by dual binding to the circumsporozoite protein (2018) (150)
Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines (2015) (149)
High-dose dexamethasone in quinine-treated patients with cerebral malaria: a double-blind, placebo-controlled trial. (1988) (148)
Sterile protection of monkeys against malaria after administration of interleukin-12 (1997) (147)
Plasmodium, human and Anopheles genomics and malaria (2002) (144)
HLA-DR-Promiscuous T Cell Epitopes from Plasmodium falciparum Pre-Erythrocytic-Stage Antigens Restricted by Multiple HLA Class II Alleles1 2 (2000) (142)
Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. (1986) (141)
Author Correction: A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite (2018) (140)
Induction of neonatal tolerance by plasmid DNA vaccination of mice. (1996) (140)
The march toward malaria vaccines. (2015) (139)
Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria (1995) (139)
Improving Protective Immunity Induced by DNA-Based Immunization: Priming with Antigen and GM-CSF-Encoding Plasmid DNA and Boosting with Antigen-Expressing Recombinant Poxvirus1 2 (2000) (139)
Hark back: Passive immunotherapy for influenza and other serious infections (2010) (139)
Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. (1993) (138)
Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates. (2010) (136)
Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. (2001) (135)
Codon Optimization of Gene Fragments EncodingPlasmodium falciparum Merzoite Proteins Enhances DNA Vaccine Protein Expression and Immunogenicity in Mice (2001) (134)
Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. (1994) (132)
NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria (1996) (130)
Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. (1991) (130)
Exploring the transcriptome of the malaria sporozoite stage (2001) (130)
Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA. (1995) (129)
Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. (2007) (125)
Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus. (1995) (125)
Primaquine for prevention of malaria in travelers. (2003) (124)
Plasmid Vaccine Expressing Granulocyte-Macrophage Colony-Stimulating Factor Attracts Infiltrates Including Immature Dendritic Cells into Injected Muscles1 (2000) (124)
Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. (1997) (122)
Antigen-specific suppressor T lymphocytes in human lymphatic filariasis. (1982) (120)
Type II Fatty Acid Biosynthesis Is Essential for Plasmodium falciparum Sporozoite Development in the Midgut of Anopheles Mosquitoes (2013) (120)
Research toward vaccines against malaria (1998) (118)
Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. (1995) (117)
DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation. (2001) (116)
Controlled Human Malaria Infection of Tanzanians by Intradermal Injection of Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites (2014) (115)
Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres (2015) (114)
Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes. (1996) (113)
Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum. (1986) (113)
Clonal selection drives protective memory B cell responses in controlled human malaria infection (2018) (112)
A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. (1992) (111)
Sequence of Plasmodium falciparum chromosomes 2, 10, 11 and 14 (2002) (111)
Seasonal profiles of malaria infection, anaemia, and bednet use among age groups and communities in northern Ghana (2003) (108)
Gene Disruption of Plasmodium falciparum p52 Results in Attenuation of Malaria Liver Stage Development in Cultured Primary Human Hepatocytes (2008) (105)
Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. (1995) (104)
Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. (2001) (104)
Induction in Humans of CD8+ and CD4+ T Cell and Antibody Responses by Sequential Immunization with Malaria DNA and Recombinant Protein1 (2004) (103)
Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection (2014) (103)
Severe anemia in young children after high and low malaria transmission seasons in the Kassena-Nankana district of northern Ghana. (2000) (102)
Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. (1997) (101)
Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. (1999) (101)
Seasonal malaria attack rates in infants and young children in northern Ghana. (2002) (101)
Nitric oxide-mediated antiplasmodial activity in human and murine hepatocytes induced by gamma interferon and the parasite itself: enhancement by exogenous tetrahydrobiopterin (1994) (100)
Incidence of symptomatic and asymptomatic Plasmodium falciparum infection following curative therapy in adult residents of northern Ghana. (2001) (98)
Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. (2002) (97)
Multistage Multiantigen Heterologous Prime Boost Vaccine forPlasmodium knowlesi Malaria Provides Partial Protection in Rhesus Macaques (2001) (96)
Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. (2001) (95)
The role of CD4+ T cells in immunity to malaria sporozoites. (1993) (94)
Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccine. (1994) (94)
A Systems-Based Analysis of Plasmodium vivax Lifecycle Transcription from Human to Mosquito (2010) (94)
Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. (1995) (93)
Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. (1990) (92)
A shotgun optical map of the entire Plasmodium falciparum genome (1999) (92)
Immune Response to a Hepatitis B DNA Vaccine in Aotus Monkeys: A Comparison of Vaccine Formulation, Route, and Method of Administration (1998) (92)
Antibodies against the Plasmodium falciparum Receptor Binding Domain of EBA-175 Block Invasion Pathways That Do Not Involve Sialic Acids (2000) (91)
CpG Oligodeoxynucleotide and Montanide ISA 51 Adjuvant Combination Enhanced the Protective Efficacy of a Subunit Malaria Vaccine (2004) (90)
Protection of Rhesus Macaques against Lethal Plasmodium knowlesi Malaria by a Heterologous DNA Priming and Poxvirus Boosting Immunization Regimen (2002) (90)
Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. (1991) (89)
Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. (2004) (88)
Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine (1991) (88)
Complete protection against Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone recognizing sporozoite surface protein 2 (1994) (88)
Age-dependent susceptibility to severe disease with primary exposure to Plasmodium falciparum. (1998) (88)
Predicting outcome in malaria: correlation between rate of exposure to infected mosquitoes and level of Plasmodium falciparum parasitemia. (1994) (87)
Determining liver stage parasite burden by real time quantitative PCR as a method for evaluating pre-erythrocytic malaria vaccine efficacy. (2001) (85)
Attacking the infected hepatocyte. (1996) (85)
Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans (2021) (85)
Malaria vaccine development (1994) (85)
Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates (2015) (84)
Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2 (1995) (84)
Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe (2013) (83)
Boosting of DNA Vaccine-Elicited Gamma Interferon Responses in Humans by Exposure to Malaria Parasites (2005) (82)
A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. (2003) (81)
Identification and Characterization of the Protective Hepatocyte Erythrocyte Protein 17 kDa Gene of Plasmodium yoelii, homolog of Plasmodium falciparum Exported Protein 1* (1996) (81)
Two Plasmodium 6‐Cys family‐related proteins have distinct and critical roles in liver‐stage development (2014) (81)
Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. (1993) (81)
Multi-gene vaccination against malaria: A multistage, multi-immune response approach. (1997) (78)
Sequence of the immunodominant epitope for the surface protein on sporozoites of Plasmodium vivax. (1985) (78)
Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. (1994) (77)
Cross-species malaria immunity induced by chemically attenuated parasites. (2013) (75)
Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. (2002) (75)
From genomics to vaccines: Malaria as a model system (1998) (75)
Duodenal string-capsule culture compared with bone-marrow, blood, and rectal-swab cultures for diagnosing typhoid and paratyphoid fever. (1984) (74)
Malaria vaccines–targeting infected hepatocytes (2000) (72)
Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope (2018) (71)
Utilization of genomic sequence information to develop malaria vaccines (2003) (71)
Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. (2012) (70)
Human lymphocyte proliferative response to a sporozoite T cell epitope correlates with resistance to falciparum malaria. (1989) (69)
Characterization of the gene encoding sporozoite surface protein 2, a protective Plasmodium yoelii sporozoite antigen. (1992) (69)
NF135.C10: A New Plasmodium falciparum Clone for Controlled Human Malaria Infections (2012) (69)
Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults (2018) (68)
Simultaneous Induction of Multiple Antigen-Specific Cytotoxic T Lymphocytes in Nonhuman Primates by Immunization with a Mixture of Four Plasmodium falciparum DNA Plasmids (1998) (68)
Plasmodium yoelii: 17-kDa hepatic and erythrocytic stage protein is the target of an inhibitory monoclonal antibody. (1995) (68)
BAFF and BAFF Receptor Levels Correlate with B Cell Subset Activation and Redistribution in Controlled Human Malaria Infection (2014) (67)
γδ T Cells Are Required for the Induction of Sterile Immunity during Irradiated Sporozoite Vaccinations (2017) (67)
DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection (2017) (67)
A human monoclonal antibody prevents malaria infection and defines a new site of vulnerability on Plasmodium falciparum circumsporozoite protein (2018) (67)
A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites (2014) (67)
Bone marrow aspirate culture superior to streptokinase clot culture and 8 ml 1:10 blood-to-broth ratio blood culture for diagnosis of typhoid fever. (1986) (66)
Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection (2018) (66)
HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteers. (1995) (66)
Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon (2017) (64)
High-throughput generation of P. falciparum functional molecules by recombinational cloning. (2004) (63)
Establishment of an In Vitro Assay for Assessing the Effects of Drugs on the Liver Stages of Plasmodium vivax Malaria (2010) (63)
Impact of transmission intensity and age on Plasmodium falciparum density and associated fever: implications for malaria vaccine trial design. (1995) (62)
Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia. (2001) (62)
Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya (2015) (61)
Preventing merozoite invasion of erythrocytes. (1996) (60)
The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. (2009) (59)
PfSPATR, a Plasmodium falciparum Protein Containing an Altered Thrombospondin Type I Repeat Domain Is Expressed at Several Stages of the Parasite Life Cycle and Is the Target of Inhibitory Antibodies* (2003) (58)
The March Toward Malaria Vaccines. (2015) (57)
Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of PfSPZ Vaccine for Malaria in Healthy Equatoguinean Men (2017) (56)
Reduction of suppressor T lymphocytes in the tropical splenomegaly syndrome. (1984) (55)
Antibody Feedback Limits the Expansion of B Cell Responses to Malaria Vaccination but Drives Diversification of the Humoral Response. (2020) (54)
Treatment of Malaria (1986) (54)
Comparison of immunity to malaria in Sudan and Indonesia: crisis-form versus merozoite-invasion inhibition. (1984) (53)
CD4+ T-Cell- and Gamma Interferon-Dependent Protection against Murine Malaria by Immunization with Linear Synthetic Peptides from a Plasmodium yoelii17-Kilodalton Hepatocyte Erythrocyte Protein (1999) (53)
Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers under Chloroquine Prophylaxis: A Randomized Controlled Trial (2016) (52)
Prospects for vaccines to protect against AIDS, tuberculosis, and malaria. (2001) (52)
A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor. (2002) (52)
Artemether in severe malaria--still too many deaths. (1996) (52)
Characteristics of severe anemia and its association with malaria in young children of the Kassena-Nankana District of northern Ghana. (2002) (51)
Persistence of Protective Immunity to Malaria Induced by DNA Priming and Poxvirus Boosting: Characterization of Effector and Memory CD8+-T-Cell Populations (2002) (51)
Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants (2019) (51)
Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides. (1997) (50)
Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein. (1995) (50)
Perspectives on malaria vaccine development. (1996) (49)
Interleukin 12induction ofinterferon y-dependent protection against malaria (1994) (49)
Mosquito Passage Dramatically Changes var Gene Expression in Controlled Human Plasmodium falciparum Infections (2016) (49)
History of malaria in the United States Naval Forces at war: World War I through the Vietnam conflict. (1993) (48)
A multilateral effort to develop DNA vaccines against falciparum malaria. (2002) (48)
Diagnosis, treatment, and prevention of malaria. (1992) (48)
Dose- and time-dependent relations between infective Anopheles inoculation and outcomes of Plasmodium falciparum parasitemia among children in western Kenya. (1997) (48)
Strategy for development of a pre-erythrocytic Plasmodium falciparum DNA vaccine for human use. (1997) (48)
Changes in the total leukocyte and platelet counts in Papuan and non Papuan adults from northeast Papua infected with acute Plasmodium vivax or uncomplicated Plasmodium falciparum malaria (2008) (48)
Plasmodium falciparum Malaria Challenge by the Bite of Aseptic Anopheles stephensi Mosquitoes: Results of a Randomized Infectivity Trial (2010) (47)
DNA inoculation with a plasmid vector carrying the hepatitis E virus structural protein gene induces immune response in mice. (1997) (47)
Polymerase chain reaction amplification from Plasmodium falciparum on dried blood spots. (1995) (46)
Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites. (1999) (46)
Pre-erythrocytic-stage immune effector mechanisms in Plasmodium spp. infections. (1997) (46)
Prevention and treatment of vivax malaria (2007) (46)
Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopes (1997) (46)
The Widal slide agglutination test, a valuable rapid diagnostic test in typhoid fever patients at the Infectious Diseases Hospital of Jakarta. (1986) (46)
Evaluation of an in vitro assay aimed at measuring protective antibodies against sporozoites. (1990) (45)
Protection of Mice against Plasmodium yoelii Sporozoite Challenge with P. yoelii Merozoite Surface Protein 1 DNA Vaccines (1998) (45)
Use of a DNA probe to detect Salmonella typhi in the blood of patients with typhoid fever (1989) (44)
Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA (2012) (44)
Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity (2021) (44)
A Subdominant CD8+ Cytotoxic T Lymphocyte (CTL) Epitope from the Plasmodium yoeliiCircumsporozoite Protein Induces CTLs That Eliminate Infected Hepatocytes from Culture (2000) (43)
Recombinant Attenuated Toxoplasma gondii Expressing the Plasmodium yoelii Circumsporozoite Protein Provides Highly Effective Priming for CD8+ T Cell-Dependent Protective Immunity Against Malaria1 (2000) (43)
The Effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine. (2009) (43)
ELISPOT assay for detection of peptide specific Interferon-γ secreting cells in rhesus macaques (2001) (42)
Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies (2018) (41)
Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model (2018) (41)
Treatment of severe typhoid fever in children with high dose dexamethasone. (1988) (40)
Cross-protection between attenuated Plasmodium berghei and P. yoelii sporozoites (2007) (40)
Comparative immunopeptidomics of humans and their pathogens. (2004) (40)
Recombinant pseudorabies virus carrying a plasmodium gene: herpesvirus as a new live viral vector for inducing T- and B-cell immunity. (1992) (40)
Controlled Human Malaria Infection Leads to Long-Lasting Changes in Innate and Innate-like Lymphocyte Populations (2017) (39)
Absence of malaria mortality in villagers with chloroquine-resistant Plasmodium falciparum treated with chloroquine. (1984) (39)
Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults. (2019) (39)
Preventing sporozoite invasion of hepatocytes. (1996) (39)
Progress toward malaria preerythrocytic vaccines. (1991) (39)
A malaria sporozoite surface antigen distinct from the circumsporozoite protein. (1990) (39)
Humoral protection against mosquito bite-transmitted Plasmodium falciparum infection in humanized mice (2017) (38)
Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia. (2002) (38)
Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines (2015) (38)
Interleukin-12 and malaria. (1995) (38)
Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report (2014) (38)
Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. (2002) (38)
Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies (2015) (37)
In vitro expression and in vivo immunogenicity of Plasmodium falciparum pre-erythrocytic stage DNA vaccines. (1998) (37)
Anemia in parasite- and recombinant protein-immunized aotus monkeys infected with Plasmodium falciparum. (2002) (37)
Expression of the chemokine MIG is a sensitive and predictive marker for antigen-specific, genetically restricted IFN-γ production and IFN-γ-secreting cells (2001) (36)
Optical mapping of Plasmodium falciparum chromosome 2. (1999) (36)
Controlled human malaria infection of healthy lifelong malaria-exposed adults to assess safety, immunogenicity and efficacy of the asexual blood stage malaria vaccine candidate GMZ2. (2019) (36)
Malaria vaccine study site in Irian Jaya, Indonesia: Plasmodium falciparum incidence measurements and epidemiologic considerations in sample size estimation. (1994) (35)
Epitope prediction algorithms for peptide-based vaccine design (2003) (35)
Induction of Biologically Active Antibodies in Mice, Rabbits, and Monkeys by Plasmodium falciparum EBA-175 Region II DNA vaccine (2001) (35)
Toward clinical trials of DNA vaccines against malaria (1997) (35)
A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1 (2020) (35)
Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells. (1992) (35)
Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development (2015) (35)
Intestinal parasites in Indochinese immigrants. (1981) (34)
Repeated infection of Aotus monkeys with Plasmodium falciparum induces protection against subsequent challenge with homologous and heterologous strains of parasite. (2000) (34)
Controlled human malaria infection with Plasmodium falciparum demonstrates impact of naturally acquired immunity on virulence gene expression (2019) (34)
Impact of Malaria Preexposure on Antiparasite Cellular and Humoral Immune Responses after Controlled Human Malaria Infection (2015) (34)
Plasmodium falciparum: exported protein-1, a blood stage antigen, is expressed in liver stage parasites. (1994) (34)
DNA vaccination as an approach to malaria control: current status and strategies. (1998) (34)
Plasmodium vivax chloroquine resistance links to pvcrt transcription in a genetic cross (2019) (34)
Construction and immunogenicity of DNA vaccine plasmids encoding four Plasmodium vivax candidate vaccine antigens. (1999) (33)
Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential (2019) (33)
Irradiated sporozoite vaccine induces cytotoxic T lymphocytes that recognize malaria antigens on the surface of infected hepatocytes. (1990) (32)
Evaluation of vaccines designed to induce protective cellular immunity against the Plasmodium yoelii circumsporozoite protein: vaccinia, pseudorabies, and Salmonella transformed with circumsporozoite gene. (1990) (32)
Plasmodium falciparum Infection of Human Volunteers Activates Monocytes and CD16+ Dendritic Cells and Induces Upregulation of CD16 and CD1c Expression (2015) (32)
Successful Induction of CD8 T Cell-Dependent Protection Against Malaria by Sequential Immunization with DNA and Recombinant Poxvirus of Neonatal Mice Born to Immune Mothers 1 (2003) (32)
Verapamil inhibits proliferation, migration and protein kinase C activity in human retinal pigment epithelial cells. (1998) (32)
RII AND RIII TYPE RESISTANCE OF PLASMODIUM FALCIPARUM TO COMBINATION OF MEFLOQUINE AND SULFADOXINE/PYRIMETHAMINE IN INDONESIA (1985) (31)
Controlled human malaria infection in Kenyan adults: A safe model that could accelerate assessment of novel drugs and vaccines in malaria endemic populations (2014) (31)
Beyond Blood Smears: Qualification of Plasmodium 18S rRNA as a Biomarker for Controlled Human Malaria Infections (2019) (30)
Alterations of blood coagulation in controlled human malaria infection (2016) (30)
Absence of antigenic competition in Aotus monkeys immunized with Plasmodium falciparum DNA vaccines delivered as a mixture. (2002) (30)
Further consideration of the clonal nature of Salmonella typhi: evaluation of molecular and clinical characteristics of strains from Indonesia and Peru (1992) (30)
Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity (2017) (30)
Immunogenicity of Well-Characterized Synthetic Plasmodium falciparum Multiple Antigen Peptide Conjugates (2001) (29)
Cytotoxic T cell reactivity and HLA‐B35 binding of the variant Plasmodium falciparum circumsporozoite protein CD8+ CTL epitope in naturally exposed Kenyan adults (1997) (29)
Prevention of malaria in travelers. (1999) (29)
Immunogenicity and Protective Efficacy of Radiation-Attenuated and Chemo-Attenuated PfSPZ Vaccines in Equatoguinean Adults (2020) (29)
Immune response gene regulation of immunity to Plasmodium berghei sporozoites and circumsporozoite protein vaccines. Overcoming genetic restriction with whole organism and subunit vaccines. (1989) (29)
Successful Human Infection with P. falciparum Using Three Aseptic Anopheles stephensi Mosquitoes: A New Model for Controlled Human Malaria Infection (2013) (28)
Delineation of Stage Specific Expression of Plasmodium falciparum EBA-175 by Biologically Functional Region II Monoclonal Antibodies (2011) (28)
Plasmodium falciparum malaria parasite var gene expression is modified by host antibodies: longitudinal evidence from controlled infections of Kenyan adults with varying natural exposure (2017) (28)
Plasmodium liver load following parenteral sporozoite administration in rodents. (2013) (28)
Research (Genomics) Is Crucial to Attacking Malaria (2000) (28)
Cures for the Third World's problems (2002) (28)
Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial (2021) (27)
Expression, Extracellular Secretion, and Immunogenicity of the Plasmodium falciparum Sporozoite Surface Protein 2 in Salmonella Vaccine Strains (2001) (27)
Plasmodium yoelii: cloning and characterization of the gene encoding for the mitochondrial heat shock protein 60. (1999) (27)
Acquired Antibody Responses against Plasmodium vivax Infection Vary with Host Genotype for Duffy Antigen Receptor for Chemokines (DARC) (2010) (27)
TDR Thirty Years On: Taking Stock and Envisioning the Future for the Special Programme for Research and Training in Tropical Diseases (2008) (27)
Molecular dissection of the human antibody response to the structural repeat epitope of Plasmodium falciparum sporozoite from a protected donor (2004) (26)
Serologic Markers of Previous Malaria Exposure and Functional Antibodies Inhibiting Parasite Growth Are Associated With Parasite Kinetics Following a Plasmodium falciparum Controlled Human Infection (2019) (26)
Chloroquine for the treatment of uncomplicated malaria in Guyana (2002) (26)
Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection (2015) (26)
Acridine orange diagnosis of Plasmodium falciparum: evaluation after experimental infection. (1994) (25)
Plasmodium falciparum: sporozoite boosting of immunity due to a T-cell epitope on a sporozoite vaccine. (1987) (25)
Rehydration and maintenance therapy of cholera patients in Jakarta: citrate-based versus bicarbonate-based oral rehydration salt solution. (1985) (25)
Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis. (1997) (25)
Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial (2021) (25)
Induction of murine cytotoxic T lymphocytes against Plasmodium falciparum sporozoite surface protein 2 (1994) (24)
PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection (2021) (24)
Antibody-mediated killing of suppressor T lymphocytes as a possible cause of macroglobulinemia in the tropical splenomegaly syndrome. (1985) (24)
Monoclonal antibodies of three different immunoglobulin G isotypes produced by immunization with a synthetic peptide or native protein protect mice against challenge with Plasmodium yoelii sporozoites (1993) (24)
Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-naïve volunteers: a pilot study (2018) (24)
Use of synthetic and recombinant peptides in the study of host-parasite interactions in the malarias. (1987) (23)
Lysis of Human Monocytic Leukemia Cells by Extracellular Adenosine Triphosphate: Mechanism and Characterization of the Adenosine Triphosphate Receptor (1993) (23)
Chemically Attenuated Blood-Stage Plasmodium yoelii Parasites Induce Long-Lived and Strain-Transcending Protection (2016) (23)
Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity (2016) (23)
Plasmodium yoelii-Infected A. stephensi Inefficiently Transmit Malaria Compared to Intravenous Route (2010) (23)
Differences in epitope recognition, isotype and titer of antisera to Plasmodium falciparum merozoite surface protein 4 raised by different modes of DNA or protein immunization. (2000) (23)
ELISPOT assay for detection of peptide specific interferon-gamma secreting cells in rhesus macaques. (2001) (22)
Expression of the chemokine MIG is a sensitive and predictive marker for antigen-specific, genetically restricted IFN-gamma production and IFN-gamma-secreting cells. (2001) (22)
Class I HLA-restricted cytotoxic T lymphocyte responses against malaria-elucidation on the basis of HLA peptide binding motifs (1996) (22)
Evaluation of a DNA probe for identifying Salmonella typhi in Peruvian and Indonesian bacterial isolates. (1988) (21)
Strengthening Mechanisms to Prioritize, Coordinate, Finance, and Execute R&D to Meet Health Needs in Developing Countries (2013) (21)
Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection (2016) (21)
Laser capture microdissection and molecular analysis of Plasmodium yoelii liver-stage parasites. (2002) (21)
Tropical medicine (2000) (21)
Malaria vaccines: attacking infected erythrocytes. (1996) (21)
Recombinase Polymerase Amplification and Lateral Flow Assay for Ultrasensitive Detection of Low-Density Plasmodium falciparum Infection from Controlled Human Malaria Infection Studies and Naturally Acquired Infections (2020) (21)
Experimental Challenge of Volunteers with Malaria (1997) (20)
Malaria--from Infants to Genomics to Vaccines (2002) (20)
DNA vaccines for malaria: the past, the present, & the future. (1997) (19)
Can malaria DNA vaccines on their own be as immunogenic and protective as prime-boost approaches to immunization? (2000) (19)
Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential (2020) (19)
Safety, tolerability, and immunogenicity of PfSPZ Vaccine administered by direct venous inoculation to infants and young children: findings from an age de-escalation, dose-escalation double-blinded randomized, controlled study in western Kenya. (2020) (18)
Malaria vaccine trials in pregnant women: An imperative without precedent. (2019) (18)
The malaria genome sequencing project: complete sequence of Plasmodium falciparum chromosome 2. (1999) (18)
Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants. (1998) (18)
Plasmodium: mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity. (2009) (17)
Immunogenicity and Protective Efficacy of aPlasmodium yoelii Hsp60 DNA Vaccine in BALB/c Mice (2001) (17)
Nucleic acid vaccines against malaria. (2002) (17)
Robust, reproducible, industrialized, standard membrane feeding assay for assessing the transmission blocking activity of vaccines and drugs against Plasmodium falciparum (2015) (17)
Nucleic acid malaria vaccines. Current status and potential. (1995) (17)
Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine. (2013) (17)
Dose dependent infectivity of aseptic, purified, cryopreserved Plasmodium falciparum 7G8 sporozoites in malaria-naive adults. (2019) (16)
Whole blood transcriptome changes following controlled human malaria infection in malaria pre-exposed volunteers correlate with parasite prepatent period (2018) (16)
Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. (2021) (16)
Assessment of age-dependent immunity to malaria in transmigrants. (1997) (16)
Inducing protective immune responses against the sporozoite and liver stages of Plasmodium. (1994) (16)
Lymphocyte response to tetanus toxoid among Indonesian men immunized with tetanus-diphtheria during extended chloroquine or primaquine prophylaxis. (1997) (16)
Lysis of human monocytic leukemia cells by extracellular adenosine triphosphate: mechanism and characterization of the adenosine triphosphate receptor. (1993) (16)
Sporozoite Route of Infection Influences In Vitro var Gene Transcription of Plasmodium falciparum Parasites From Controlled Human Infections. (2016) (16)
A multiplex qPCR approach for detection of pfhrp2 and pfhrp3 gene deletions in multiple strain infections of Plasmodium falciparum (2019) (16)
Mutating the anchor residues associated with MHC binding inhibits and deviates CD8+ T cell mediated protective immunity against malaria. (2007) (16)
Protective efficacy against malaria of a combination sporozoite and erythrocytic stage vaccine. (1996) (15)
Immune responses and protection of Aotus monkeys immunized with irradiated Plasmodium vivax sporozoites. (2011) (15)
Systems analysis and controlled malaria infection in Europeans and Africans elucidate naturally acquired immunity (2021) (15)
T lymphocytes from mice immunized with irradiated sporozoites eliminate malaria from hepatocytes. (1990) (15)
Susceptibility of Panamanian Aotus lemurinus lemurinus to sporozoite-induced Plasmodium falciparum (Santa Lucia) infection. (1999) (15)
Humoral immune responses against Plasmodium vivax MSP1 in humans living in a malaria endemic area in Flores, Indonesia. (1998) (15)
Progress with PfSPZ Vaccine, a radiation attenuated Plasmodium falciparum sporozoite vaccine (2014) (15)
Mycobacterial induction of activated killer cells: possible role of tyrosine kinase activity in interleukin-2 receptor alpha expression (1992) (15)
HIV Treatments Reduce Malaria Liver Stage Burden in a Non-Human Primate Model of Malaria Infection at Clinically Relevant Concentrations In Vivo (2014) (14)
Multidose Priming and Delayed Boosting Improve PfSPZ Vaccine Efficacy against Heterologous P. falciparum Controlled Human Malaria Infection. (2020) (14)
Low immunogenicity of a Plasmodium vivax circumsporozoite protein epitope bound by a protective monoclonal antibody. (1992) (14)
Ivermectin for causal malaria prophylaxis: a randomised controlled human infection trial (2019) (14)
Protection against inhalation anthrax by immunization with Salmonella enterica serovar Typhi Ty21a stably producing protective antigen of Bacillus anthracis (2017) (14)
Transcriptome profiling reveals functional variation in Plasmodium falciparum parasites from controlled human malaria infection studies (2019) (14)
Induction of cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein by immunization with soluble recombinant protein without adjuvant (1993) (14)
Immune response of humans to the circumsporozoite protein of Plasmodium falciparum: limited T cell response to the immunodominant central repeat region. (1988) (13)
Lymphocyte proliferative response and subset profiles during extended periods of chloroquine or primaquine prophylaxis (1996) (13)
Humoral immune response to tetanus-diphtheria vaccine given during extended use of chloroquine or primaquine malaria chemoprophylaxis. (1998) (13)
Acridine orange detection of Plasmodium falciparum malaria: relationship between sensitivity and optical configuration. (1991) (13)
Prospects and strategies for development of DNA vaccines against malaria. (1994) (12)
Mefloquine treatment for uncomplicated falciparum malaria in young children 6-24 months of age in northern Ghana. (2007) (12)
Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite (2016) (12)
Lymphocyte response to tetanus toxin T-cell epitopes: effects of tetanus vaccination and concurrent malaria prophylaxis. (1999) (12)
Proteome-wide analysis of a malaria vaccine study reveals personalized humoral immune profiles in Tanzanian adults (2020) (12)
Chloroquine resistant Plasmodium falciparum on the island of Flores, Indonesia. (1983) (12)
Is Saglin a mosquito salivary gland receptor for Plasmodium falciparum? (2019) (12)
Malaria: A protective paradox (2006) (12)
Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia. (1997) (12)
Part I - Malaria (2003) (11)
Haemoglobin dynamics in Papuan and non-Papuan adults in northeast Papua, Indonesia, with acute, uncomplicated vivax or falciparum malaria (2013) (11)
Preerythrocytic Malaria Vaccine Development (1993) (11)
Activation of TCR Vδ1+ and Vδ1−Vδ2− γδ T Cells upon Controlled Infection with Plasmodium falciparum in Tanzanian Volunteers (2019) (11)
The Equatoguinean Malaria Vaccine Initiative: From the Launching of a Clinical Research Platform to Malaria Elimination Planning in Central West Africa (2020) (11)
Assessing the Parasight-F test in northeastern Papua, Indonesia, an area of mixed Plasmodium falciparum and Plasmodium vivax transmission. (2002) (10)
Interleukin-12- and Gamma Interferon-Dependent Protection against Malaria Conferred by CpG Oligodeoxynucleotide in Mice (2002) (10)
Development of a Live Attenuated Bivalent Oral Vaccine Against Shigella sonnei Shigellosis and Typhoid Fever. (2016) (10)
Antibodies to the circumsporozoite protein and protective immunity to malaria sporozoites. (1993) (10)
Vaccines Against Human Hookworm Disease (2004) (10)
Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults (2022) (10)
Optimization of antibody responses of a malaria DNA vaccine in Aotus monkeys (1996) (10)
Microbial disease in humans: A genomic perspective. (2001) (10)
The Malaria Genome Sequencing Project (1998) (10)
Malaria sporozoites and circumsporozoite protein bind sulfated glycans: carbohydrate binding properties predicted from sequence homologies with other lectins. (1993) (9)
Opposing effects of filariasis and chronic malaria on immunoregulatory T lymphocytes. (1983) (9)
Identification of a nonameric H-2Kk-restricted CD8+ cytotoxic T lymphocyte epitope on the Plasmodium falciparum circumsporozoite protein (1995) (9)
Exploratory analysis of the effect of helminth infection on the immunogenicity and efficacy of the asexual blood-stage malaria vaccine candidate GMZ2 (2021) (9)
A CTL epitope on the circumsporozoite protein of P. yoelii. (1990) (9)
Model yoelii Plasmodium T Cells in the + Malaria Initiated by CD 8 Antigen-Specific Adaptive Immunity Against IL-12 and NK Cells Are Required for (1999) (9)
Pyrimethamine-sulfadoxine still effective against Plasmodium falciparum in Jayapura, Irian Jaya: RI-type resistance in 2 of 18 patients. (1987) (9)
Plasmodium falciparum gametocytemia in Kenyan children: associations among age, intensity of exposure to transmission, and prevalence and density of subsequent gametocytemia. (1997) (9)
An Efficient Production Process for Extracting Salivary Glands from Mosquitoes (2019) (9)
HLA-A*01-Restricted Cytotoxic T-Lymphocyte Epitope from the Plasmodium falciparum Circumsporozoite Protein (2001) (8)
Streptokinase clot culture compared with whole blood culture for isolation of Salmonella typhi and S. paratyphi A from patients with enteric fever. (1988) (8)
Save the children : Malaria (2004) (8)
Partial protection against malaria by immunization with Leishmania enriettii expressing the Plasmodium yoelii circumsporozoite protein. (1995) (7)
Mapping of safe and early chemo-attenuated live Plasmodium falciparum immunization identifies immune signature of vaccine efficacy (2020) (7)
Molecular malaria surveillance using a novel protocol for extraction and analysis of nucleic acids retained on used rapid diagnostic tests (2020) (7)
The malaria genome sequencing project. (1998) (7)
Controlled human malaria infections using aseptic, purified cryopreserved Plasmodium falciparum sporozoites administered by needle and syringe (2014) (6)
Effect of immune regulatory pathways after immunization with GMZ2 malaria vaccine candidate in healthy lifelong malaria-exposed adults. (2020) (6)
PROLONGED INCUBATION IMPROVES THE MICRO-SCALE IN-VITRO TEST FOR DRUG SENSITIVITY OF PLASMODIUM FALCIPARUM (1984) (6)
Immunological responses of neonates and infants to DNA vaccines. (2006) (6)
An overview of malaria vaccine development efforts (1999) (6)
A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection (2022) (6)
An antitoxic vaccine for malaria (1996) (6)
157 Cryopreservation of Plasmodium falciparum Sporozoites and Sanaria® PfSPZ Vaccine (2013) (6)
Nanotechnological immunoassay for rapid label-free analysis of candidate malaria vaccines. (2021) (6)
Effective treatment and prevention of typhoid fever: updated. (1984) (6)
Strategies for the Control of Malaria (1994) (6)
Splenectomy in massive tropical splenomegaly: two-to six-year follow-up in 14 patients. (1988) (6)
Plasmodium falciparum LipB mutants display altered redox and carbon metabolism in asexual stages and cannot complete sporogony in Anopheles mosquitoes (2021) (6)
Plague in the United States: the "black death" is still alive. (1980) (6)
Diagnostic performance and comparison of ultrasensitive and conventional rapid diagnostic test, thick blood smear and quantitative PCR for detection of low-density Plasmodium falciparum infections during a controlled human malaria infection study in Equatorial Guinea (2021) (6)
HLA degenerate T‐cell epitopes from Plasmodium falciparum liver stage‐specific antigen 1 (LSA‐1) are highly conserved in isolates from geographically distinct areas (2000) (6)
Microbial Disease in Humans: A Genomic Perspective (2012) (6)
Preventing cytoadherence of infected erythrocytes to endothelial cells and noninfected erythrocytes. (1996) (5)
PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial (2022) (5)
Induction of immunity following vaccination with a chemically attenuated malaria vaccine correlates with persistent antigenic stimulation (2018) (5)
Tropical medicine. Recent advances. (2000) (5)
Correction: Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccination (2016) (5)
Cytotoxic T lymphocytes in humans exposed to Plasmodium falciparum by immunization or natural exposure. (1994) (5)
Cultivation of the exoerythrocytic stage ofPlasmodium berghei in primary cultures of mouse hepatocytes and continuous mouse cell lines (1989) (5)
Knockout of Anopheles stephensi immune gene LRIM1 by CRISPR-Cas9 reveals its unexpected role in reproduction and vector competence (2021) (5)
Immune Response against the Exp-1 Protein of Plasmodium falciparum Results in Antibodies That Cross-React with Human T-Cell Lymphotropic Virus Type 1 Proteins (1998) (5)
Sequencing the genome of Plasmodium falciparum (1998) (5)
Infectious disease. Research (genomics) is crucial to attacking malaria. (2000) (5)
Prevention of malaria. (1991) (4)
Rationale and approaches to constructing preerythrocytic malaria vaccines. (1995) (4)
DNA vaccination against malaria (1996) (4)
Travel vaccines. (1999) (4)
PLASMODIUM FALCIPARUM PARASITE DYNAMICS DETERMINED BY QPCR AFTER CONTROLLED HUMAN MALARIA INFECTION IN SEMI-IMMUNES FROM GABON (2017) (4)
The development of a multivalent DNA vaccine for malaria (2004) (4)
Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa (2022) (4)
A Mosquito Pick-and-Place System for PfSPZ-Based Malaria Vaccine Production (2020) (4)
A monoclonal antibody directed against the sporozoite stage of Plasmodium vivax binds to liver parenchymal cells. (1992) (4)
Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response (2022) (4)
Expansion of Functional Myeloid-Derived Suppressor Cells in Controlled Human Malaria Infection (2021) (4)
Plasmodium vivax: freeze-fracture studies on the ultrastructure of the sporozoites within the salivary gland of the mosquito Anopheles stephensi. (1995) (4)
Quantification of Plasmodium knowlesi versus Plasmodium falciparum in the rhesus liver: implications for malaria vaccine studies in rhesus models (2020) (4)
Predicting the effects of malaria vaccines on the population dynamics of infection and disease. (1996) (4)
Immunogenicity and Protective Efficacy of a Plasmodium yoelii Hsp 60 DNA Vaccine in BALB / c Mice (2001) (4)
Clonal evolution and TCR specificity of the human TFH cell response to Plasmodium falciparum CSP (2022) (4)
DISEASE STATES AND VACCINES: SELECTED CASES (2003) (4)
Caregiver and community perceptions and experiences participating in an infant malaria prevention trial of PfSPZ Vaccine administered by direct venous inoculation: a qualitative study in Siaya County, western Kenya (2020) (3)
Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres (2015) (3)
Iron supplementation in prevention of severe anaemia and malaria (1997) (3)
Feasibility of direct venous inoculation of the radiation-attenuated Plasmodium falciparum whole sporozoite vaccine in children and infants in Siaya, western Kenya. (2020) (3)
Incidence of Plasmodium falciparum malaria infection in 6-month to 45-year-olds on selected areas of Bioko Island, Equatorial Guinea (2021) (3)
Development and field-testing of the synthetic SPf66 malaria vaccine. (1996) (3)
A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite (2018) (3)
In vitro survival and retention of infectivity of Plasmodium yoelii sporozoites over extended periods of time. (1994) (3)
Role of human Pegivirus infections in whole Plasmodium falciparum sporozoite vaccination and controlled human malaria infection in African volunteers (2021) (3)
Plasmodium falciparum: from genomic sequence to vaccines and drugs. (2000) (3)
Progress in prevention and treatment of malaria (1996) (3)
Transient knockdown of Anopheles stephensi LRIM1 using RNAi increases Plasmodium falciparum sporozoite salivary gland infections (2021) (3)
CHAPTER 96 – Malaria (2011) (3)
In vitro production of infectious Plasmodium falciparum sporozoites (2022) (3)
Production of monoclonal antibodies against a 19-kD recombinant Plasmodium vivax MSP1 for detection of P. vivax malaria in Turkey. (2004) (3)
Author Correction: A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite (2018) (3)
REHYDRATION AND MAINTENANCE THERAPY OF CHOLERA PATIENTS IN JAKARTA: CITRATE-BASED VS. BICARBONATE-BASED ORAL REHYDRATION SALT SOLUTIONS (1986) (2)
Reduction of mortality in chloramphenicol-treated patients with severe typhoid fever by high dose dexamethasone. (1983) (2)
Two cases of long-lasting, sub-microscopic Plasmodium malariae infections in adults from coastal Tanzania (2019) (2)
Adaptive clinical trials of three PfSPZ products for development of a whole sporozoite vaccine that prevents Plasmodium falciparum infection, disease and transmission (2012) (2)
THE ROLE OF REGULATORY T CELLS IN THE CONTROL OF PARASITE GROWTH AND CLINICAL OUTCOMES FOLLOWING CONTROLLED HUMAN MALARIA INFECTION IN SEMI-IMMUNE KENYAN ADULTS (2018) (2)
Cytotoxic T lymphocyte (CTL) adherence assay (CAA): a non-radioactive assay for murine CTL recognition of peptide-MHC class I complexes. (1997) (2)
Antibody feedback limits the expansion of cognate memory B cells but drives the diversification of vaccine-induced antibody responses (2019) (2)
Malaria (part 1). Lessons from Somalia and General Slim. (1974) (2)
A First for Human Vaccinology: GMP Compliant Radiation Attenuation of Plasmodium falciparum Sporozoites for Production of a Vaccine Against Malaria (2022) (2)
Efficient infection of non-human primates with purified, cryopreserved Plasmodium knowlesi sporozoites (2022) (2)
Presidential address: The American Society of Tropical Medicine and Hygiene in the last half century: from apparent anachronism to international leader and innovator. (2002) (2)
Plasmodium 18S rRNA of intravenously administered sporozoites does not persist in peripheral blood (2018) (2)
Automated Mosquito Salivary Gland Extractor for PfSPZ-based Malaria Vaccine Production (2021) (2)
DNA-based vaccines against malaria and other diseases - from the laboratory to the clinic (2001) (2)
Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates (2015) (2)
A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria (2022) (2)
Cryopreserved Sporozoites with and without the Glycolipid Adjuvant 7DW8-5 Protect in Prime-and-Trap Malaria Vaccination. (2022) (2)
OPEC and the structural changes in the oil market: The outlook after the counter-revolution (1985) (2)
Ruth Nussenzweig (1928–2018) Malaria Vaccine and Immunology Pioneer (2018) (2)
12. A Cryopreserved metabolically-active non-replicating vaccine against malaria (2008) (2)
Induction of protective polyclonal antibodies by immunization with Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. (1995) (2)
IDENTIFYING HEXAHYDROQUINOLINES AS NEW ANTIMALARIALS WITH POTENT BLOOD STAGE AND TRANSMISSION-BLOCKING ACTIVITY (2017) (1)
Malaria vaccine development : pre-erythrocytic stages (1990) (1)
In vitro growth inhibition of Plasmodium falciparum by sera from tropical splenomegaly syndrome patients. (1986) (1)
An Oligonucleotide Probe for Detecting Plasmodium falciparum: An Analysis of Clinical Specimens (1987) (1)
Clonal evolution and specificity of the human T follicular helper cell response to Plasmodium falciparum circumsporozoite protein (2021) (1)
In Reply: Malaria Vaccines (1990) (1)
Blood Products for Spanish Influenza: A Future H5N1 Treatment? (2007) (1)
Early whole blood transcriptional responses to radiation-attenuated Plasmodium falciparum sporozoite vaccination in malaria naïve and malaria pre-exposed adult volunteers (2021) (1)
Chapter 90 – Malaria (2006) (1)
86. Towards the development of a cryopreserved live attenuated vaccine against malaria (2007) (1)
An efficient single‐cell based method for linking human T cell phenotype to T cell receptor sequence and specificity (2021) (1)
Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report (2014) (1)
Efficacy, T cell activation and antibody responses in accelerated Plasmodium falciparum sporozoite chemoprophylaxis vaccine regimens (2022) (1)
Cryopreservation of Anopheles stephensi embryos (2022) (1)
Identification of the Glycan Binding Profile of Human and Rodent Plasmodium Sporozoites. (2021) (1)
Immunoprofiles associated with controlled human malaria infection and naturally acquired immunity identify a shared IgA pre-erythrocytic immunoproteome (2021) (1)
Oil economists handbook 1984 : by Gilbert Jenkins Applied Science Publishers, London and New York, 282 pp, 1984 (1984) (1)
Born to Immune Mothers Recombinant Poxvirus of Neonatal Mice by Sequential Immunization with DNA and Cell-Dependent Protection Against Malaria Successful Induction of CD 8 T (2003) (1)
Atypical B cells are a normal component of immune responses to vaccination and infection in humans (2020) (1)
Protective Immunity Against Malaria T Cell-Dependent + Effective Priming for CD 8 Circumsporozoite Protein Provides Highly Plasmodium yoelii Expressing the Toxoplasma gondii Recombinant Attenuated (2000) (1)
SOLUBLE HLA-G LEVEL EFFECT ON GMZ2 SPECIFIC IgG PRODUCTION AFTER IMMUNISATION (2017) (1)
Haemoglobin dynamics in Papuan and non-Papuan adults in northeast Papua, Indonesia, with acute, uncomplicated vivax or falciparum malaria (2013) (1)
Progress in Development of an Automated Mosquito Salivary Gland Extractor: A Step Forward to Malaria Vaccine Mass Production (2021) (1)
Immunology and pathogenic mechanisms of malaria (1992) (1)
Tropical Medicine (1945) (1)
Autologous lymphoblastoid cell lines stably transfected with Plasmodium falciparum circumsporozoite protein as targets in cytotoxic T-lymphocyte assays. (1997) (1)
Pre-erythrocytic and asexual erythrocytic stage whole-organism malaria vaccines (2010) (1)
Molecular and functional properties of human Plasmodium falciparum CSP C-terminus antibodies (2023) (1)
Increased levels of anti-PfCSP antibodies in post-pubertal females versus males immunized with PfSPZ Vaccine does not translate into increased protective efficacy (2022) (1)
Immunological profiles associated with distinct parasitemic states in volunteers undergoing malaria challenge in Gabon (2022) (1)
Immunology, pathophysiology, and treatment of malaria (1990) (1)
Humoral protection against mosquito bite-transmitted Plasmodium falciparum infection in humanized mice (2017) (0)
Transient knockdown of Anopheles stephensi LRIM1 using RNAi increases Plasmodium falciparum sporozoite salivary gland infections (2021) (0)
Epstein T Cell Immunity + Hepatic CD 8 Live Attenuated Malaria Vaccine Designed to Protect Through (2014) (0)
Technique de prediction de liaison peptide-proteine (2003) (0)
Atovaquone/Proguanil Therapyfor Plasmodium falciparum and Plasmodium vivax Malariain Indonesians Who LackClinical Immunity (2002) (0)
Vaccination procedures against malaria (2003) (0)
Liquid nitrogen vapor phase cold chain distribution of cryopreserved malaria vaccine (2016) (0)
Malaria Sporozoites and C ircumsporozoite Proteins Bind Specifically to Sulfated Glyr (1992) (0)
Protection against inhalation anthrax by immunization with Salmonella enterica serovar Typhi Ty21a stably producing protective antigen of Bacillus anthracis (2017) (0)
sporozoite development in the midgut of Anopheles mosquitoes 2 (2013) (0)
Lipoic acid biosynthesis is essential for Plasmodium falciparum transmission and influences redox response and carbon metabolism of parasite asexual blood stages (2020) (0)
Anti-homotypic affinity maturation improves human B cell responses against a repetitive parasite antigen (2018) (0)
This information is current as Sporozoite Vaccinations Sterile Immunity during Irradiated T Cells Are Required for the Induction of δγ (2017) (0)
Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity (2016) (0)
Incidence of Plasmodium Falciparum Malaria Infection in 6-month- to 45-year-olds on Bioko Island, Equatorial Guinea. (2021) (0)
Structural studies of human antibody responses against leading malaria vaccine antigen PfCSP (2018) (0)
Aseptic Anopheles insects therefrom obtained aseptic Plasmodium sporozoites, and a vaccine comprising the aseptic Plasmodium sporozoites (2003) (0)
Plasmodium yoelii: expression of circumsporozoite protein and sporozoite surface protein 2 by sporozoites in culture. (1995) (0)
Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity (2017) (0)
Cryopreservation of Anopheles stephensi embryos (2022) (0)
Plasmodium 18S rRNA biomarker clearance after FDA-approved antimalarial treatment in controlled human malaria infection trials (2023) (0)
Use of DNA vaccine technology to overcome obstacles to malaria vaccine development and to utilize data from the malaria genome project (1998) (0)
Mefloquine (MQ) single dose 20 mg/kg treatment of falciparum malaria was evaluated in 186 children of 6-24 months of age in northern Ghana (2007) (0)
Preventing Malaria: Part 2 of Somalia and General Slim (1994) (0)
Role of Human Pegivirus Infections in Whole P. falciparum Sporozoite Vaccination and Controlled Human Malaria Infection in African Volunteers (2020) (0)
Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya (2015) (0)
Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies (2015) (0)
Efficient infection of non-human primates with purified, cryopreserved Plasmodium knowlesi sporozoites (2022) (0)
A Randomized, Double-Blind,Placebo-Controlled, Dose-Ranging Trialof Tafenoquine for Weekly Prophylaxisagainst Plasmodium falciparum (2003) (0)
Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines (2015) (0)
Malaria field studies at NAMRU-2, Indonesia. (1993) (0)
Author response: A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites (2014) (0)
Sex-Specific Differences in Cytokine Induction by the Glycolipid Adjuvant 7DW8-5 in Mice (2022) (0)
for the Treatment of Mediterranean Visceral Leishmaniasis (2003) (0)
A Computational Pipeline for High-Throughput T-Cell Epitope Prediction (2003) (0)
Role of human Pegivirus infections in whole Plasmodium falciparum sporozoite vaccination and controlled human malaria infection in African volunteers (2021) (0)
Early whole blood transcriptional responses to radiation-attenuated Plasmodium falciparum sporozoite vaccination in malaria naïve and malaria pre-exposed adult volunteers (2021) (0)
Author response: Proteome-wide analysis of a malaria vaccine study reveals personalized humoral immune profiles in Tanzanian adults (2020) (0)
Caregiver and community perceptions and experiences participating in an infant malaria prevention trial of PfSPZ Vaccine administered by direct venous inoculation: a qualitative study in Siaya County, western Kenya (2020) (0)
Plasmodium 18S rRNA of intravenously administered sporozoites does not persist in peripheral blood (2018) (0)
Cells into Injected Muscles Infiltrates Including Immature Dendritic Colony-Stimulating Factor Attracts Granulocyte-Macrophage Plasmid Vaccine Expressing (2000) (0)
Development of a new syringe/needle accessible cryovial for storage of human injectable vaccines and immunotherapeutics compatible with storage below −150°C and use in all clinical environments (2015) (0)
The impact of Loa loa microfilaraemia on research subject retention during a whole sporozoite malaria vaccine trial in Equatorial Guinea (2022) (0)
Efficacy, T cell activation and antibody responses in accelerated Plasmodium falciparum sporozoite chemoprophylaxis vaccine regimens (2022) (0)
Diagnostic performance and comparison of ultrasensitive and conventional rapid diagnostic test, thick blood smear and quantitative PCR for detection of low-density Plasmodium falciparum infections during a controlled human malaria infection study in Equatorial Guinea (2022) (0)
Alterations of blood coagulation in controlled human malaria infection (2016) (0)
Recombinant Protein Immunization with Malaria DNA and Cell and Antibody Responses by Sequential T + and CD4 + Induction in Humans of CD8 (2004) (0)
34. Modeling a LNVP cold chain for distribution of the PfSPZ Vaccine (2010) (0)
Surface Protein 1 DNA Vaccines Merozoite P . yoelii Sporozoite Challenge with Plasmodium yoelii Protection of Mice against (1998) (0)
Robust, reproducible, industrialized, standard membrane feeding assay for assessing the transmission blocking activity of vaccines and drugs against Plasmodium falciparum (2015) (0)
Incidence of Plasmodium falciparum malaria infection in 6-month to 45-year-olds on selected areas of Bioko Island, Equatorial Guinea (2021) (0)
Adaptive clinical trials of three PfSPZ products for development of a whole sporozoite vaccine that prevents Plasmodium falciparum infection, disease and transmission (2012) (0)
Recombinant Leishmania Containing Genes Encoding Proteins From Infectious Disease Agents and Method of Inducting Cellular Immune Response. (1993) (0)
Iron supplementation inprevention of severeanaemia and malaria (1997) (0)
Chapter 17 – Typhoid Fever* (2006) (0)
057 Vaccines: The Sanaria experience (2013) (0)
Modelling liquid nitrogen vapour phase (LNVP) cold chain distribution of cryopreserved PfSPZ vaccine for malaria elimination (2015) (0)
Cellular and antibody response in GMZ2-vaccinated Gabonese volunteers in a controlled human malaria infection trial (2022) (0)
Purnomo Projodipuro 11 April 1933-10 May 2013 Obituary (2014) (0)
A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection (2022) (0)
Immunoprofiles associated with controlled human malaria infection and naturally acquired immunity identify a shared IgA pre-erythrocytic immunoproteome (2021) (0)
Stabilization of vaccines (2020) (0)
Controlled human malaria infections using aseptic, purified cryopreserved Plasmodium falciparum sporozoites administered by needle and syringe (2014) (0)
Characterization of the gene encoding sporozoite surface protein 2 , a protective Plasmiodiwn ) ' oelii sporozoite antigen (0)
Thermostabilization by foam drying of a recombinant anthrax vaccine (2015) (0)
1631: Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (pfspz vaccine) in Tanzanian Adults (2016) (0)
Evaluation ofaninvitro assayaimedatmeasuring protective antibodies against sporozoites (1990) (0)
Infection Redistribution in Controlled Human Malaria with B Cell Subset Activation and BAFF and BAFF Receptor Levels Correlate and (2014) (0)
Two cases of long-lasting, sub-microscopic Plasmodium malariae infections in adults from coastal Tanzania (2019) (0)
Multiple HLA Class II Alleles Pre-Erythrocytic-Stage Antigens Restricted falciparum Plasmodium HLA-DR-Promiscuous T Cell Epitopes from and Alessandro (2000) (0)
Is Saglin a mosquito salivary gland receptor for Plasmodium falciparum? (2019) (0)
Tlymphocytes frommiceimmunized withirradiated sporozoites eliminate malaria fromhepatocytes (1990) (0)
Development of a new cryovial with septum for use with cryopreserved human eukaryotic cell vaccines and products compatible with storage below -150 °C (2020) (0)
Oil shock, policy response and implementation -- report of Harvard energy security project: by Alvin L. Alm and Robert J. Weiner Ballinger, Cambridge, MA, 1984, 256 pp, [pound sign]26.50 (1984) (0)
Healthcare in the United States: a Matter of Right or Privilege? (2008) (0)
Competition and the utility industry -- Who will survive? (1995) (0)
Unmanaged Care: Should There be a Right to Health Care in the United States? (2006) (0)
Randomized, Placebo-Controlled Trialof Atovaquone/Proguanil for the Preventionof Plasmodium falciparum or Plasmodiumvivax Malaria among Migrantsto Papua, Indonesia (2002) (0)
The micro in vitro test for malaria drug resistance in Irian Jaya: 28 and 48-hour incubation yield similar probit analysis findings. (1985) (0)
The exception that proves the rule: Virulence gene expression at the onset of Plasmodium falciparum blood stage infections (2022) (0)
Purnomo Projodipuro (April 11, 1934–May 10, 2013) (2013) (0)
World Conference on Pre-Erythrocytic Stage Malaria Vaccine Development: Current Status and Future Prospects Held in Bethesda, Maryland on April 12-15, 1989 (1989) (0)
Genome, proteome, and immunome data explain why 6 month controlled human malaria infection with sporozoites of the Pf7G8 clone of Plasmodium falciparum is a rigorous predictor of the efficacy of the PfNF54-based PfSPZ Vaccine in Africa (2021) (0)
Providing Ancillary Care in Clinical Research: A Case of Diffuse Large B-Cell Lymphoma during a Malaria Vaccine Trial in Equatorial Guinea (2020) (0)
Devices and methods for production of haematophagous organisms and parasites for vaccine production (2003) (0)
The complexity of protection against liver-stage malaria (1999) (0)
Plasmid PYCSP DNA and attenuated vaccinia virus-PYCSP recombinant confers additive protection against P. yoelii challenge (1998) (0)
Cellular and antibody response in GMZ2-vaccinated Gabonese volunteers in a controlled human malaria infection trial (2022) (0)
CLINICAL LABORATORY PARAMETERS AMONG ADULT MALES DURING A PRIMAQUINE CHEMOPROPHYLAXIS TRIAL IN IRIAN JAYA, INDONESIA (1995) (0)
Progress with PfSPZ Vaccine, a radiation attenuated Plasmodium falciparum sporozoite vaccine (2014) (0)

This paper list is powered by the following services:

Other Resources About Stephen L. Hoffman

en.wikipedia.org

What Schools Are Affiliated With Stephen L. Hoffman?

Stephen L. Hoffman is affiliated with the following schools: